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Liver neoplasms: imaging characterization*
Neoplasias hepáticas: caracterização por métodos de imagem
Dario Ariel Tiferes1, Giuseppe D’Ippolito2
A wide range of both benign and malignant neoplasms may occur in the liver. Although the characterization
of focal hepatic lesions may represent a diagnostic challenge for radiologists, typical imaging findings in these
lesions allow a correct diagnosis. The present study is aimed at reviewing imaging findings both in the most
frequent benign and malignant focal lesion found in the adult liver.
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Uma grande variedade de tumores benignos e malignos ocorre no fígado. Embora a caracterização de lesões
hepáticas focais possa ser um desafio para o radiologista, a maioria das lesões se apresenta com caracterís-
ticas de imagem que permitem o seu diagnóstico. O objetivo deste trabalho é o de rever os principais aspec-
tos de imagem dos tumores hepáticos benignos e malignos mais comumente encontrados no fígado adulto.
Unitermos: Fígado; Neoplasia; Imagem por ressonância magnética; Ultra-sonografia; Tomografia computa-
dorizada.
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ranging between 0.4% and 20% in autopsy
studies(1,2), and representing a very frequent
incidental finding on imaging studies, par-
ticularly US. In most cases, hemangiomas
are small (≤ 3.0 cm), and may be multiple
in up to 50% of patients(3). Microscopically,
hemangiomas consist of vascular spaces
irregular in size, lined by a single layer of
endothelial cells and separated by fibrous
septa(4).
The finding of a hyperechogenic, ho-
mogeneous and well-defined nodule at US
is highly indicative of hemangioma(3) (Fig-
ure 1). TC findings include the presence of
hypodense lesion in the precontrast phase
of the study. After intravenous injection of
iodinated contrast agent, the typical en-
hancement pattern includes peripheral
globular enhancement in the arterial and
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INTRODUCTION
A wide range of benign and malignant
tumors occurs in the liver. Although the
characterization of focal hepatic lesions
may represent a challenge for radiologists,
most of lesions can be diagnosed on the
basis of imaging findings. The present study
is aimed at reviewing the most frequent im-
aging findings related to benign and malig-
nant hepatic tumors in adult individuals.
This paper describes the main characteris-
tics of hemangioma, focal nodular hyper-
plasia, adenoma, hepatocellular carcinoma,
intrahepatic cholangiocarcinoma and he-
patic metastasis observed at ultrasonogra-
phy (US) computed tomography (CT) and
magnetic resonance imaging (MRI).
HEMANGIOMA
Hemangioma is the most frequent be-
nign tumor of the liver, with an incidence
0100-3984 © Colégio Brasileiro de Radiologia e Diagnóstico por Imagem
portal phases, progressive centripetal en-
hancement and persistence of enhancement
in the equilibrium phase(3,5,6) (Figure 2). A
complete non-opacification of the lesion
does not hinder the diagnosis of heman-
gioma. Frequently, large lesions may not be
completely enhanced and the center of the
lesion remains hypodense, possibly repre-
senting fibrosis, former hemorrhage and
cystic alterations(7,8).
Small hemangiomas (≤ 1.5 cm) fre-
quently are early and completely contrast-
enhanced. This enhancement pattern re-
sults from the small vascular spaces size
causing an increase in the inside blood (and
contrast mean) flow velocity. The persis-
tence of the contrast-enhancement during
the equilibrium phase is useful in the dif-
ferentiation of hemangiomas from other
Figure 1. Hemangiomas at US. On A, three hemangiomas with a characteristic aspect (arrows); on B,
another atypical hemangioma, with echogenic borders and hypoechogenic center (arrow).
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hypervascular lesions such as focal nodu-
lar hyperplasia and some types of metastases
presenting a more rapid wash-out pattern(7).
At MRI, hemangiomas are character-
ized by lesions with well-defined margins,
hyperintense signal on T2-weighted se-
quences persisting with high echo times
(around 180 ms)(2,5). The gadolinium up-
take pattern is similar to the iodinated con-
trast-mean uptake pattern found at CT (Fig-
ure 3). With T2-weighted sequences and
intravenous, paramagnetic contrast-en-
hanced dynamic study, MRI sensitivity and
specificity in the diagnosis of hemangio-
mas reach 98%(5).
Despite its high specificity in the diag-
nosis of hemangiomas, radionuclide scin-
tigraphy(9) is not routinely utilized because
of its low accuracy in the diagnosis of small
and/or multiple lesions.
Hemangiomas may present atypical, al-
though quite suggestive sonographic pat-
terns. For example, they may present an
echogenic halo and a hypoechogenic cen-
ter(10) (Figure 1). Giant hemangiomas (typi-
cally with > 6 cm or 10 cm) frequently
present heterogeneous echotexture, with a
hypoechoic center. Additionally, in steatotic
livers, hemangiomas frequently present as
a hypoechogenic nodule as a result of the
high hepatic parenchymal echogenicity.
Most hemangiomas with an atypical pat-
tern at US present typical intravenous con-
trast uptake patterns at CT and MRI(7,8).
Other less frequent findings of heman-
giomas include calcified, hyalinized and
cystic/multilocular lesions. Hemangiomas
also may be exophytic or pedunculated,
and not infrequently present small, adja-
cent arterial-portal venous shunt determin-
ing transitory perfusional disorder in the
adjacent hepatic parenchyma observed at
CT and MRI(7).
FOCAL NODULAR HYPERPLASIA
Focal nodular hyperplasia (FNH) is de-
fined as a nodule constituted by apparently
normal hepatocytes, occurring in a liver
with a normal histological aspect. It is the
second more frequent benign hepatic tu-
mor, with a reported incidence of 0.9%,
predominantly in women (female-to-male
ratio = 8:1) and in young patients. About
20% of patients present with multiple le-
sions and in association with hepatic he-
mangiomas(11).
Histologically, FNH may be classified
into classic (80%) and non-classic (20%)
presentations. The classic form presents
three components: abnormal nodular archi-
tecture, vascular malformations and prolif-
eration of biliary ducts. The non-classic
Figure 2. Typical hepatic hemangioma at CT. Precontrast phase (A), arterial phase (B), portal-venous
phase (C) and equilibrium phase (D). Note the peripheral, globular uptake with centripetal distribution.
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Figure 3. Typical hepatic hemangioma at MRI (arrows). A: FSE T2-weighted image with fat-saturation,
echo time = 90 ms; B: FSE T2-weighted image without fat saturation, TE 180 ms; C: precontrast, GRE
T1-weighted image; D: portal phase, contrast-enhanced GRE T1-weighted image. Note the remarkable,
persistent hyperintense signal on the T2-weighted image and peripheral, globular uptake in the post-
contrast, portal phase.
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form presents two of the three components,
including the ductal proliferation(11).
FNH pathogenesis is still to be com-
pletely understood. Vascular malformation
and/or vascular injury are suggested as
probable mechanisms for its develop-
ment(12). Association with steroids is con-
troversial. This tumor is usually asymptom-
atic and, in this case, it does not require any
treatment(13).
Usually, FNH is an incidental finding at
imaging studies, especially after the dis-
semination and improvement of intrave-
nous contrast-enhanced dynamic CT and
MRI studies(14,15). At US, this lesion pre-
sents a non-specific pattern, being poorly
visualized. Generally, this lesion presents
like a slightly hypoechogenic or hyperecho-
genic nodule and cannot be definitively
characterized by this method(15).
Generally, classic FNH can be effectively
characterized at CT and MRI. Currently,
helical CT and particularly multidetector
CT allow a multiphase hepatic study (arte-
rial, portal and equilibrium phases of he-
patic contrast-enhancement), that is indis-
pensable in the evaluation and correct char-
acterization of the tumor vascularization.
Typical CT findings of FNH include lobu-
lated, well-defined lesion, isoattenuating or
slightly hypoattenuating in the precontrast
phase, and a significant, homogeneous
contrast-enhancement in the arterial phase,
with rapid washout in the portal and equi-
librium phases. Usually, a small central,
star-like scar consisting of vascular malfor-
mations is observed, tending to delayed
contrast-enhancement(14,15) (Figure 4).
At MRI, classic FNH is depicted as a
slightly hypointense lesion on T-weighted
images, and with a subtle hyperintensity on
T2-weighted images. In 85% of these le-
sions, a central scar can be identified with
a higher intensity signal than the rest of the
lesion on T2-weighted images. The pattern
of intravenous contrast-enhancement of
FNH is similar to the one described for CT
images(14). In the presence of such charac-
teristics, the MRI diagnostic specificity
reaches 98%(14) (Figure 5).
Atypical FNHs may present as large,
heterogeneous lesions in multiple sites. The
tumor may present a lower degree of con-
trast-enhancement, absence of the central
scar enhancement and delayed contrast-
enhancement of the pseudocapsules. Ex-
ceptionally, central punctiform calcifica-
tions may be observed(15). Differentiating
FNH from other benign (adenomas) and
malignant lesions (hepatocarcinomas,
fibrolamellar carcinomas and hypervascu-
larized metastases) may be extremely dif-
ficult, requiring histopathological study.
ADENOMA
Hepatocellular adenoma is a rare benign
neoplasm, usually found in women with a
history of long-term use of oral contracep-
tives(16). Although the pathogenic mecha-
nism of this lesion is still to be completely
understood, the utilization of estrogenic or
Figure 5. Focal nodular hyperplasia at MRI (arrows). A: FSE, fat-saturated, T2-weighted image, echo
time = 90 ms; B: GRE, fat-saturated T1-weighted images; C: arterial phase, contrast-enhanced, GRE
T1-weighted image; D: equilibrium phase, contrast-enhanced, GRE T1-weighted image. Note the remark-
able arterial enhancement and washout in the equilibrium phase. The central scar presents hypointense
signal on T2-weighted image and delayed enhancement in the equilibrium phase.
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Figure 4. Typical focal nodular hyperplasia at CT (arrows). Precontrast phase (A), arterial phase (B), portal
phase (C) and equilibrium phase (D). Note the early contrast mean uptake in the arterial phase and rapid
washout in the portal phase. The central scar remains hypoattenuating at the early phases, with delayed
filling in the equilibrium phase.
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androgenic substances, particularly over
long periods of time, increases significantly
the incidence of this tumor(16). Patients with
glycogen storage disease also present an
increased risk for developing adenomas(17).
Adenomas have been most frequently
detected as incidental findings in patients
submitted to multi-phase, contrast-en-
hanced CT or MRI studies for other unre-
lated signs or symptoms. Approximately
70% of adenomas are solitary and 30%,
multiple(18,19). The patients use to be as-
ymptomatic, with normal results for labo-
ratory hepatic function tests and alpha-fe-
toprotein levels. Very large adenomas may
present intratumoral bleeding and rupture,
causing abdominal pain and hypoten-
sion(20).
Histologically, adenomas consist of
large cords of cells resembling normal
hepatocytes separated by dilated sinusoids
with arterial perfusion. Portal venous sup-
ply and biliary ducts are absent(21). Ad-
enomas cells contain large amounts of gly-
cogen and lipid, the latter rarely macro-
scopically found(19).
Most rarely, this lesion may undergo
malignant degeneration to hepatocellular
carcinoma, despite former long-term stabil-
ity. Significant increase in the size of the
tumor and in alpha-fetoprotein serum lev-
els suggests a diagnosis of malignant trans-
formation(22,23).
The term hepatic adenomatosis is ap-
plied to cases of multiple adenomas (> 10)
found in patients without known risk fac-
tors, and possibly representing a distinctive
entity(24). In spite of presenting histologic
characteristics similar to solitary adenomas,
hepatic adenomatosis may present a high
potential for growth, hemorrhage and,
eventually malignant transformation(21).
Adenomas can be detected at US, but
normally do not present a typical echo-
graphic pattern, and requires supplemen-
tary CT or MRI for a better evaluation of
the lesion(23).
Imaging findings indicating the diagno-
sis of adenoma at multi-phase, contrast-en-
hanced CT include the presence of a soli-
tary (or, eventually, multiple) lesion with
well-defined borders, and sometimes a
pseudocapsule. The presence of fat or
intralesional hemorrhage foci is quite char-
acteristic. The lesion tends to be isoattenu-
ating to the hepatic parenchyma in the
precontrast phase, with homogeneous con-
trast-enhancement in the arterial phase,
tending to become isoattenuating to the
hepatic parenchyma in the portal and equi-
librium phases(23).
At MRI, imaging findings suggesting
adenoma include hyperintense signal on
T1-weighted images and slightly hyperin-
tense on T2-weighted images. The signal
loss on out-of-phase, gradient-echo se-
quences indicates the presence of intra-
lesional fat, and constitutes a sign suggest-
ing the diagnosis of adenoma. The pattern
of paramagnetic contrast-enhancement is
similar to the one observed at CT(18,25) (Fig-
ure 6).
Very heterogeneous adenomas present-
ing atypical findings may require additional
studies (MRI utilizing hepato-specific con-
trast agents), or even biopsy to rule-out the
possibility of malignancy. Differential di-
agnoses for adenomas include other
hypervascular lesions that occur in young
adults without association with other
hepatopathies, such as FNH, fibrolamellar
hepatocarcinoma and metastasis(23).
Prognosis in cases of adenomas is still
to be fully established. In many cases, ad-
enomas may remain stable for long periods
of time, or even may regress with the dis-
continuation of the estrogen medication.
Episodes of hemorrhage and malignant
transformation, although rare, remain as the
main clinical problems. Some criteria indi-
cating surgical resection of adenomas in-
clude large lesions (> 5 cm in diameter) and
presence of symptoms related to intra-
tumoral hemorrhage(20,23). In patients with
a high number of lesions (adenomatosis),
liver transplant has been proposed, consid-
ering its higher risk for malignancy(18,20).
HEPATOCELLULAR CARCINOMA
Hepatocellular carcinoma (HCC) gen-
erally occurs as a complication from he-
patic cirrhosis, particularly the one caused
by hepatitis B and C viruses(26,27), with a
prevalence in cirrhotic livers removed at
transplantation reaching 14%(28).
Patients with hepatic cirrhosis can be
evaluated by US, CT and MRI. Although
each of these methods presents a particu-
larity, the capacity of detecting a focal le-
sion depends on the contrast between the
lesion and the parenchyma, which may be
affected by the presence of fat, necrosis and
fibrosis. Hepatic alterations related to fi-
brosis and nodular regeneration associated
to perfusional alterations resulting from
portal hypertension, usually present in
these patients, represent a challenge to ra-
diologists in the detection and characteriza-
tion of HCC at the different imaging meth-
ods. Ultrasound, particularly, presents sig-
nificant limitations in the evaluation of cir-
rhotic nodules in the liver. Considering the
higher risk of cirrhotic patients for devel-
oping HCC, upon detection of any solid
nodule at US, the investigation should pro-
ceed with CT or MRI. It is essential that
both CT and MRI are performed utilizing
intravenous contrast agents, and including
multi-phase studies in the contrast-en-
hanced arterial phase for detection and
characterization of HCC(27).
Nodular lesions in a cirrhotic liver may
be classified into two major categories: re-
generative nodules and dysplastic or neo-
plastic nodules(29). Regenerative nodules
represent parenchymal areas increased as a
response to necrosis and circulatory alter-
ations. Nodules > 3–5 mm are called
macroregenerative nodules, but rarely
reach more than 20 mm. Generally, nodules
with > 20 mm are dysplastic. Regenerative
nodules may contain iron and, in this case,
they are called siderotic nodules(29).
Although regenerative nodules are
present in all of cirrhotic livers, they are
seen in a minority of patients at CT, and in
about 50% o cases at MRI, the siderotic
nodules being more clearly seen(27,30). Sid-
erotic nodules may present spontaneously
hyperattenuating at non-contrast-enhanced
CT, and, normally, at MRI present with
hypointense signal on T2-weighted se-
quences, as a function of the presence of
iron inside them. On T1-weighted se-
quences, such nodules use to present a
subtle hypointense or isointense signal to
the surrounding hepatic parenchyma and,
less frequently, hyperintense signal. Typi-
cally, these nodules do not enhance at con-
trast-enhanced CT in the arterial phase, and
in the portal-venous phase they enhance
homogeneously, similarly to the hepatic
parenchyma; thus they are indistinguish-
able(27) (Figure 7).
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Dysplastic nodules present morphologi-
cal characteristics occupying an intermedi-
ate position among the characteristics
found in regenerative nodules and HCC.
One of the classifications adopted includes
low-grade dysplastic nodules, high-grade
dysplastic nodules, high-grade dysplastic
nodules with HCC foci, and the HCC itself.
Histologic studies demonstrate that
through this progression, the number of
portal tracts decrease and new arterial ves-
sels develop within the lesions. These are
determining findings in the characteriza-
tion of these lesions(27,29).
Despite the utilization of multi-phase,
contrast-enhanced techniques including ac-
quisition in the hepatic arterial phase, CT
and MRI still lack accuracy in the detection
of HCC. Correlation studies evaluating liv-
ers removed from patients submitted to
transplant have demonstrated CT and MRI
sensitivity in the detection of HCC of
59%–68% and 50%, respectively. Addi-
tionally, the sensitivity in the detection of
the total number of lesions was 37%–44%
for CT, and 50% for MRI(28,31). These re-
sults reflect the inclusion of many nodules
< 1.0 cm in diameter, remarkably difficult
to be detected by imaging methods.
HCC presents a variable appearance at
CT and MRI. Although the hyperintense
signal on MRI T2-weighted sequences sug-
gests HCC, the sinal may present as hypo,
iso-, or hyperintense in relation to the ad-
jacent liver on T1- and T2-weighted im-
ages(27,31,32).
Most of times, small HCCs are hyper-
vascularized, with preferential enhance-
ment in the arterial phase, and wash-out in
the portal-venous phase imaging, where the
attenuation/signal is similar to the one of
the liver (Figure 7). A minority of tumors
is hypovascular, and is more clearly iden-
tified in the portal-venous and equilibrium
phases imaging(28,31). Large lesions (> 5.0
cm) tend to be heterogeneous, and may
present necrosis, fatty metamorphosis and
tumor capsule(27) (Figure 8). In principle,
any vascular nodule found in a patient with
hepatopathy should be considered as highly
suspect for HCC, particularly those with >
2.0 cm in diameter. A sign observed at con-
trast-enhanced CT and MRI may help in the
diagnosis of other hepatic lesions (for ex-
ample, regenerative or dysplastic nodules).
With a certain frequency, HCCs present a
fibrotic pseudocapsule that is enhanced in
delayed phases or may present low-con-
trast-enhancement in the equilibrium
phase, in comparison with the adjacent
hepatic parenchyma(32).
Some authors advocate the utilization of
arteriography with lipiodol, a substance
that preferentially links to tumor cells and
can be seen at delayed CT studies (at least
three weeks after intra-arterial lipiodol in-
jection)(33). However, this method has not
been frequently utilized in the diagnosis of
HCC, considering that, besides its inva-
siveness, the intense uptake by the lesions
impairs the management of the progression
and viability of the lesion. So lipiodol has
Figure 6. Hepatic adenoma at MRI (arrows). A: FSE, fat-saturated T2-weighted image, echo time = 90 ms; B: FSE, fat-saturated T2-weighted image, echo
time = 180 ms; C: in-phase, GRE T1-weighted image; D: out-of-phase GRE T1-weighted image; E: arterial phase, contrast-enhanced, GRE T1-weighted image;
F: portal phase, contrast-enhanced, GRE T1-weighted image. Note the remarkable signal loss of the lesion in the out-of-phase GRE T1-weighted sequence,
indicating the fat component of the lesion.
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been utilized in association with chemo-
therapic drugs and hepatic artery emboliza-
tion, as palliative therapeutic measures for
non-resectable hepatic tumors or in patients
waiting for liver transplantation. Despite
difficult, the evaluation of the treatment
efficacy, must be performed by means of
the study of intravenous contrast-enhanced
areas, which usually translates into tumor
viability(33).
Screening for HCC is indicated for pa-
tients undergoing clinical conditions allow-
ing curative treatment, taking age, presence
of comorbidities and degree of the hepatic
function involvement into consideration.
Although screening for HCC with US
and alpha-fetoprotein dosage every 6
months is usual in our environment, ran-
domized studies are still required to evalu-
ate the efficacy and cost-benefit ratio of
these studies. In some regions of the world
where the prevalence of HCC is high,
screening tests are more rigorous, includ-
ing alpha-fetoprotein dosage every two
months, abdominal ultrasound every three
months, and CT or MRI every six months(26).
Fibrolamellar hepatocarcinoma is an
uncommon type of hepatocarcinoma with
clinical, prognostic and histopathologic
features different from classic HCC found
in cirrhotic livers. This lesion occurs pref-
erentially in young patients with no history
of underlying hepatopathies and absence of
serum tumor markers(34).
Frequent imaging findings of fibro-
lamellar HCC include large, well-defined,
lobulated, heterogeneous masses in non-
cirrhotic livers, with radiate septa and a
central scar with fibrotic components. Cal-
cifications (better evaluated by CT) are
seen in about 50% of cases, almost exclu-
sively in the central scar regions. Intrave-
nous contrast-enhanced dynamic studies
demonstrate preferentially arterial, hetero-
geneous vascularization. On delayed im-
ages, there is a trend to persistent contrast
uptake by the central scar, demonstrating
the fibrotic component of this region (Fig-
ure 9). At MRI, the tumor generally pre-
sents hypointense signal on T1-weighted
sequences, and hyperintense signal on T2-
weighted sequences. The central scar pre-
sents hypointense signal on T2-weighted
sequences. Such finding is useful in the
differentiation of other tumors that may
Figure 7. Hepatocellular carcinoma at MRI (arrows). A: FSE, fat-saturated T2-weighted image, echo time
= 90 ms; B: GRE, fat-saturated T1-weighted image; C: arterial phase, contrast-enhanced GRE T1-weighted
image; D: equilibrium phase, contrast-enhanced GRE T1-weighted image. Note signs of hepatopathy,
with small, sparse, regenerative siderotic nodules more clearly seen with hypointense signal on T2-weighted
images. The hepatocellular carcinoma in the left lobe presents a remarkable arterial enhancement and
washout in the equilibrium phase, with contrast-enhancement of the fibrotic pseudocapsule.
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Figure 8. Large hepatocellular carcinoma at MRI (arrows). A: FSE T2-weighted image without fat-satu-
ration, echo time = 180 ms; B: fat-saturated GRE T1-weighted image; C: arterial phase, contrast-en-
hanced GRE T1-weighted image; D: portal phase, contrast-enhanced GRE T1-weighted image. The hepa-
tocellular carcinoma presents heterogeneous signal on T2-weighted images, remarkable arterial enhance-
ment and rapid washout in the portal phases, with capsule definition.
C D
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present with central scars, especially in
cases of FNH where the central scar pre-
sents hyperintense signal on MRI T2-
weighted sequences(34).
CHOLANGIOCARCINOMA
Although biliary tract tumors are not in-
cluded in the scope of the present study,
imaging findings of some intrahepatic
cholangiocarcinomas are described, con-
sidering that they should be included in the
differential diagnosis of primary hepatic
lesions.
Cholangiocarcinoma is an adenocarci-
noma originating in the epithelium of the
biliary ducts. It is the second primary ma-
lignant tumor most frequently found in the
liver, after HCC. It is associated to intrahe-
patic lithiasis, choledocal cyst, Caroli’s
disease, primary sclerosing cholangitis, and
C. sinensis infection(35). The tumor may
originate in any portion of the biliary epi-
thelium, and may be classified into intra-
hepatic (peripheral or hilar) or extrahepatic.
Peripheral cholangiocarcinoma originates
in secondary intrahepatic ducts and hilar
cholangiocarcinoma originates in the right
and left hepatic ducts or their confluence,
receiving the name of Klatskin tumor(36).
Peripheral cholangiocarcinomas usually
present as a solid, well-defined, lobulated
mass with peripheral contrast-uptake at CT
and MRI. Generally, it appears as a bulky
tumor at the moment of the diagnosis, be-
cause of the absence of symptoms in the
early phases of the disease, where fre-
quently dilatation of the biliary tract is not
found, in contrast to the hilar presentation.
Focal dilatation of biliary ducts and capsu-
lar retraction usually is found in 30% of
cases (Figure 10). The persistent contrast-
uptake by the tumor in delayed phases is a
finding frequently described as a result of
the presence of intralesional fibrotic tis-
sue(37–40).
HEPATIC METASTASES
Hepatic metastasis is the most frequent
found malignant lesion of the liver. A cor-
rect diagnosis is essential for determining
the therapeutic conduct and prognosis.
Accurate information on the number of
lesions, as well as their extent constitute a
prerequisite for the success of the surgical
resection and therapeutic monitoring. Be-
sides the screening for hepatic metastasis,
the oncologic patient requires the differen-
tiation between hepatic metastasis and
other benign hepatic nodules frequently,
incidentally found on imaging studies(41).
Ultrasound presents a limited sensitiv-
ity for detecting hepatic metastasis, rang-
ing between 50% and 70%(42). Most of
times, small metastases, especially those <
1.0 cm or isoechoic to the hepatic paren-
chyma, are not detectable by US. The most
typical US finding in cases of hepatic me-
tastasis is a hypo or isoechoic lesion sur-
rounded by a hyperechoic halo giving the
lesion the so called “target” or bull’s eye”
aspect. The presence of a halo has a high
sensitivity for the diagnosis of malignancy
(about 85%)(43). Despite the lower cost and
higher availability, this method presents a
lower reproducibility as compared with CT
and MRI, difficulting the management of
the lesion progression(42,43).
Figure 10. Intrahepatic cholangiocarcinoma at MRI (arrows). A: FSE, fat-saturated T2-weighted image,
echo time = 90 ms; B: FSE T2-weighted image without fat-saturation, echo time = 180 ms; C: precontrast
GRE T1-weighted image; D: portal phase, contrast-enhanced GRE T1-weighted image. Heterogeneous
lesion with remarkable contrast mean uptake. Note the mild, adjacent hepatic capsular retraction.
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Figure 9. Fibrolamellar hepatocellular carcinoma. A young patient without underlying hepatopathy. Non-
contrast-enhanced CT image: large, heterogeneous mass in the right lobe, with central calcifications (A).
Contrast-enhanced CT image: heterogeneous contrast-enhancement is observed, with delimitation of
other lesions in the left lobe (B).
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CT in association with MRI is consid-
ered as the main imaging method for
screening hepatic metastases in oncologic
patients, considering the better spatial reso-
lution and higher sensitivity (about 75%)
and specificity in the detection and charac-
terization of focal hepatic lesions. Addi-
tionally, CT allows the evaluation of further
associated diffuse, hepatic alterations, be-
sides studying the whole abdomen. The
helical technology, especially with multi-
detector tomographs, allows the perfor-
mance of multi-phase (hepatic precontrast,
arterial, portal-venous and equilibrium
phases) contrast-enhanced and non-con-
trast-enhanced hepatic studies, which is
essential for an appropriate evaluation of
the liver, particularly in the context of ma-
lignancy. Additionally an appropriate
evaluation of the hepatic portal, arterial and
venous threes can be performed. 3D angio-
graphic reconstruction can be performed,
allowing the correlation between the le-
sions and the major vascular branches(44,45).
Most metastases are hypovascular and
present as hypoattenuating nodules in re-
lation to the hepatic parenchyma in the
portal-venous phase, with heterogeneous
or ring-shaped contrast-enhancement (Fig-
ure 11). Some neoplasms (for example:
renal cell carcinomas, thyroid carcinomas,
breast carcinomas, carcinoid tumors, neu-
roendocrine tumors and melanomas) may
develop hypervascular hepatic metastases
which can be more clearly identified in the
arterial phase because of the early and tran-
sitory contrast agent uptake, tending to
become isoattenuating to the parenchyma
in the portal-venous phase(44,45) (Figure 12).
Small hypoattenuating nodules, particu-
larly those with < 1.0 cm, may be hardly
characterized at CT. In these cases, MRI
can aid in the diagnostic evaluation, con-
sidering the method specificity in the char-
acterization of small cysts and hemangio-
mas usually present, including in the group
of oncologic patients(46).
MRI presents sensitivity (about 75%)
and specificity very similar to CT in the
evaluation of secondary hepatic lesions.
Similarly to CT, the conventional technique
for evaluation of the liver utilizes intrave-
nous paramagnetic contrast agent, with
series acquired during the hepatic arterial,
portal-venous and equilibrium phases. T2-
weighted images are extremely important
in the characterization of lesions, and rep-
resent an additional advantage as compared
with CT, particularly in the case of small
lesions(42,46) (Figure 11). The utilization of
hepato-specific contrast agents, such as
superparamagnetic iron oxide, seems to
increase the accuracy of this method in the
detection of metastases, especially the
small ones(47). However, taking its high cost
into consideration, this type of contrast
agent has not been routinely utilized.
CONCLUSION
With the dissemination of imaging di-
agnosis devices as well as their increasingly
widespread utilization, the occurrence of
incidentally found hepatic nodules has be-
come more and more frequent in patients
submitted to imaging studies or screening
for tumors(48–51). The technological devel-
opment of these apparatuses has allowed
the detection of increasingly smaller le-
sions, difficulting their characterization
that later might be affected by the findings
of pseudo-hepatic lesions at contrast-en-
hanced CT and MRI(52,53). Recognizing the
main imaging findings of the most frequent
hepatic tumors and some of their charac-
teristics(54) may positive and definitely help
the radiologist in the approach and man-
agement of this group of patients.
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